Phathom Finally Prints an Operating Profit — and the Stock Says It Doesn't Matter

Q3 revenue up 71% and a second straight profitable quarter, while the equity sits 51% below its July high on a patent fight Phathom can't control

PHAT · Earnings Call · 2026-10-29

The P&L stopped being the problem

For a company that spent its first three years as a public entity burning cash in public, Phathom's third quarter is a genuine inflection on the printed page. Revenue of $84.7 million grew 71% year over year and 14% sequentially; the company booked $5.8 million of operating profit excluding stock-based compensation and $2.1 million of cash from operations — the second consecutive quarter of both. Total revenue has gone from essentially zero in 2023 to $74 million in the last filed quarter, and the call put Q3 at $84.7 million. Operating income, which bottomed near -$116 million in early 2025, has swung about $42 million in three quarters. Sanjeev Narula did not undersell it: “for a second consecutive quarter, we have delivered operating profitability and generated cash from operations, ending the quarter with $184.6 million in cash and cash equivalent” — Sanjeev Narula, Chief Financial and Business Officer · 2026-10-29. Against a cash hold requirement of roughly $119 million under the Revenue Interest Financing Agreement, that is headroom, not a bridge round. Management reaffirmed full-year revenue of $310–325 million, which implies a Q4 of roughly $93–108 million and a 10–28% sequential step-up — the largest quarter-over-quarter hill of the year, into a quarter where Narula pre-warned that Medicare Part D catastrophic coverage will push gross-to-net discounting higher. The one blemish is mechanical: Gross margin fell to roughly 78% in Q3 from a 87.2% peak, which management attributed to one-time cost-of-revenue charges. Asked directly whether fulfilment costs were becoming a recurring drag, Narula was categorical that it was a one-time manufacturing charge and that distribution costs are flat with volume.

Access First: renaming the problem from friction to inertia

What actually changed this quarter is vocabulary, and the vocabulary change is the strategy. Through the spring and summer, the operative word was friction. On the July call, Steve Basta framed it as a workflow problem: “the actual friction is how much work does it take in an office to get VOQUEZNA covered and what's the experience between the moment that a physician prescribes when the patient is trying to fill the script” — Steven Basta, President and CEO · 2026-07-30. That word has now fallen out of the top decliner list as sharply as it once rose, and in its place comes a new, more optimistic diagnosis: inertia.

I do not view that there is anything I would describe as resistance. It is more that there is inertia. What the inertia looks like is physicians just have a habit of prescribing to the patient's local pharmacy because that pharmacy is in the patient's records in the EHR.
Steve Basta, President and CEO · 2026-10-29

The commercial program built around that reframe is Access First — a suite of education, prior-authorization coaching, and most importantly a new $0 copay offering available only through the BlinkRx mail-order channel. The logic is behavioral, not economic: at $25 a month versus a free generic PPI, the physician's decision calculus still tilts to the generic; at zero, the conversation becomes which drug is better for the patient. Basta conceded a single carve-out — Massachusetts prohibits the differential copay — and Narula insisted the incremental buydown is immaterial to gross-to-net and more than offset by incremental filled scripts. This is where the company's keyword history is most informative. Pocket cost, affordability, patient support and medical notes are all fresh this quarter. A year ago, on the October 2025 call, Basta described the barrier as three decades of habit: “The major impediment candidly is 30 years of habit. They've been prescribing PPIs for 30 years.” — Steven Basta, President and CEO · 2025-10-30 The company has effectively decided that if habit is the enemy, you buy the habit change with a zero-dollar receipt. Notably, primary care and erosive-esophagitis patient language both dropped hard in the current-quarter keyword set — consistent with Basta's flat statement that GI stays the priority and primary care expansion is not a 2027 event.

What the tape is actually pricing: May 3, 2032

Here is the tension. Price to revenue sits near 3.6x, down 39% year over year, and the tape tells a blunter story: PHAT is down 41% in 90 days and 51% from its July 10 peak of $12.61, against a whole-history drawdown of 88.6% from the 2020 high. A company beating and reaffirming does not fall 41% on operations. It falls on patent risk. On October 21, BDR Pharmaceuticals sued the FDA over the agency's application of the GAIN Act to extend new chemical entity exclusivity, with a second purported ANDA filer moving to consolidate. The FDA opened a 30-day public docket on October 23 and Phathom intervened. This is the sequel to the Citizen Petition the company won in June 2025, which secured Orange Book exclusivity through May 3, 2032. Basta would not forecast the path — “Litigation goes through many steps and we're going to try to not predict exactly what happens in each step of this process because it's an inherently fluid process” — Steve Basta, President and CEO · 2026-10-29 — and that refusal, however prudent, leaves the equity's largest variable unmodeled by management. The litigation is now a top-of-mind keyword for the first time.

The second PCAB is now a tailwind, not a threat

The other overhang is competitive, and here management's framing has hardened into confidence. Dennis Ding offered the LDL-lowering analogy — a heavily genericized market where a branded launch expanded the category — and Basta embraced it: “the second product entrant actually shifts much more awareness to the need to take patients to the new class of products, and the market leader benefits along with the introduction of the second product” — Steve Basta, President and CEO · 2026-10-29. That is a more assertive version of the same argument made in February, when he noted the company was at roughly 1% of the 110-million-prescription PPI market, and in July, when he argued “when a second product launches into a category, it changes physician perception from thinking about the first drug in the category as just a single drug to now thinking about the need to shift to that category” — Steven Basta, President and CEO · 2026-07-30. Crucially, management declined to forecast pricing. Asked whether a second entrant would compress price the way the PPI category did, Basta passed: they have not seen the entrant's pricing or strategy. Payer negotiations, he said, have not shifted at all. The nearer-term catalyst is internal: top-line Phase II EoE data this quarter, full 24-week data by the end of Q1, and then an end-of-Phase-II conversation with the FDA in 2027 that could yield a written request and the six-month pediatric exclusivity extension — the one lever that adds patent life rather than defending it. For a $503 million market cap with revenue annualizing near $340 million, the arithmetic on the screen is unusually stark. What changed this quarter is that the operating business finally works. What has not changed is that the thing determining the share price sits in a courtroom and a federal docket, and management — for good reasons — will not put a number on it.